The publication method
A closer reading, before a wider claim.
The purpose of Sema Evidence, the questions it covers and the commercial context of its provider reviews.
Why this publication exists
Sema Evidence examines claims made around semaglutide microdosing. The reading asks who was studied, which product a record identifies and what outcome it measured or authorizes. Those questions help define the scope of a claim; they do not decide what treatment an individual should receive.
What the source reader does
The source-pair reader lets you choose two named public records and read fixed, reviewed summaries. Product labeling is identified separately from trial reporting. The interface does not calculate a comparative benefit, generate a clinical conclusion or match you to a study population.
The people and work behind the pages
The articles use this publication’s editorial identity. Their evidence comes from the linked public documents, not from patient treatment experience, laboratory testing or a clinician’s unperformed review. Dates indicate source checks and cannot guarantee that a commercial offer remains unchanged.
Our commercial position
This site is part of the CoreAge Rx promotional publishing network. CoreAge receives first commercial placement, with disclosure beside its features and reviews. That placement is not independent evidence of quality, clinical superiority or suitability for you. We are an educational publication, not a clinic or pharmacy.